STAGE IV RENAL CELL CANCER AJCC V8

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare genetic condition (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood suppl…

This study is for people with kidney cancer that has spread to other parts of the body. It compares standard immunotherapy drugs (like nivolumab and axitinib) alone versus the same drugs plus surgery to remove the affected kidney. The goal is to see if adding surgery helps patien…

This study is for people with advanced kidney cancer that has spread and cannot be removed by surgery. It tests whether adding a precise, high-dose form of radiation (SABR) to the main tumor, alongside standard immunotherapy drugs, can better control the cancer and delay its grow…

This early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…

This early-stage trial tests whether adding a live bacteria product (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) is safe and helps control metastatic kidney cancer. About 33 adults with advanced kidney cancer that has spread will receive either the standard …

This study is testing a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare cancers of the urinary and reproductive systems that have spread to other parts of the body. The goal is to see if this mix can shrink tumors better than any single dr…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests whether adding a fiber supplement called inulin gel to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer better than immunotherapy alone. About 55 adults with kidney cancer that has spread or is locally advanced will …

This early-stage trial explores whether a ketogenic (low-carb, high-fat) diet can help standard immunotherapy drugs work better in people with advanced melanoma or kidney cancer. About 60 adults will follow the diet while receiving treatment, and researchers will monitor safety a…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…

This study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…